All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Zanubrutinib granted approval for patients with R/R CLL/SLL and R/R MCL by China’s National Medical Products Administration

Jun 5, 2020

On June 3, 2020, China’s National Medical Products Administration (NMPA) granted approval for zanubrutinib, a Bruton tyrosine kinase inhibitor, in two indications — for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in adult patients who have received ≥ 1 prior therapies, and for the treatment of mantle cell lymphoma (MCL) in adult patients who have received ≥ 1 prior therapy.1

This decision was based on data from the pivotal single-arm phase II study (NCT03206918) of zanubrutinib in patients with relapsed/refractory (R/R) CLL (n = 82) and R/R SLL (n = 9). The overall response rate was 62.6%, the complete response rate was 3.3%, the partial response (PR) rate was 59.3%, and the PR with lymphocytosis rate was 22%. The most common adverse events (AEs) were neutropenia, thrombocytopenia, hematuria, purpura, anemia, leukopenia, pneumonia, upper respiratory tract infection, hemorrhage, and rash. The incidence of any Grade ≥ 3 AE was 69.2%. The incidence of serious AEs was 19.8%, and the most common serious AE was pneumonia.

Approval of zanubrutinib in R/R MCL was based on results from a single-arm pivotal phase II study conducted in 86 patients in China (NCT03206970). The overall response rate was 83.7%, with a complete response rate of 68.6% and a PR rate of 15.1%. The most common AEs were neutropenia, rash, leukopenia, thrombocytopenia, and anemia. The incidence of serious AEs was 15.1%, and common serious AEs included pneumonia (8.1%), hemorrhage (2.3%), and thrombocytopenia (2.3%).

The U.S. Food and Drug Administration previously granted an accelerated approval to zanubrutinib for the treatment of adult patients with R/R MCL, click here to read more.

  1. GlobeNewswire. BeiGene announces the approval of BRUKINSA™ (zanubrutinib) in China for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma and relapsed/refractory mantle cell lymphoma. Published June 3, 2020. Accessed June 4, 2020.